O'Niel Mallory B, Runge Christina L, Friedland David R, Kerschner Joseph E
Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.
Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee2Division of Pediatric Otolaryngology, Medical College of Wisconsin, Milwaukee.
JAMA Otolaryngol Head Neck Surg. 2014 Jun;140(6):513-20. doi: 10.1001/jamaoto.2014.484.
Magnet-based implantable auditory assist devices (MIAADs) are a recent development in bone-anchored hearing devices. This report increases the number of children studied with specific outcome criteria and provides detailed solutions to avoid device use difficulties in other centers considering this device.
To assess hearing thresholds, use rates, and complications in children implanted with a MIAAD for conductive hearing loss.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of children implanted with an MIAAD at an ambulatory care quaternary referral center since the Food and Drug Administration approved the Sophono device (Sophono Inc) for use in the United States (May 2011 through January 2013). Ten pediatric patients were implanted for conductive hearing loss (14 ears; mean age at implantation, 9 years [range, 3.8-17.2 years]). Diagnoses included aural atresia (n = 7) and chronic ear disease and cholesteatoma (n = 3).
Implantation of MIAAD and management of skin complications.
Demographics, hearing thresholds, use rates, and complications were assessed.
After fitting with the magnetic baseplate and sound processor, the mean (SD) aided pure-tone average was 20.2 (6.0) dB hearing level (HL), with a mean (SD) functional gain of 39.9 (12.4) dB HL. There were no surgical complications. Negative outcomes were assessed following fitting of the sound processor. The skin complication rate was 35.7%, including skin breakdown (n = 2) and pain and erythema (n = 5), which resulted in decreased use of the device for these patients. Intervention included decreasing the magnet strength, graduated wearing schedule, antibiotic ointment, barrier protection, and reoperation for well widening with Alloderm (LifeCell Corporation) placement. Patients without skin complications are consistent users of their device, with an average daily use of 8 to 10 hours.
The MIAAD device has equivalent levels of hearing restoration to other previously described methods of intervention for children with conductive hearing loss. This early report indicates high rates of skin difficulties and a need for improved methods of implantation, magnetic baseplate fitting, and device use. We suggest decreased magnet strength at the initial fitting, a graduated wearing schedule, caution with patients who have a history of skin issues from a bone-anchored hearing aid or multiple surgical procedures, and parent counseling regarding potential skin irritation.
基于磁体的可植入听觉辅助装置(MIAADs)是骨锚式听力装置的一项最新进展。本报告增加了依据特定结局标准进行研究的儿童数量,并为其他考虑使用该装置的中心提供了避免装置使用困难的详细解决方案。
评估植入MIAAD治疗传导性听力损失患儿的听力阈值、使用率及并发症情况。
设计、地点和参与者:对自美国食品药品监督管理局批准Sophono装置(Sophono公司)在美国使用以来(2011年5月至2013年1月),在一家门诊四级转诊中心植入MIAAD的儿童进行回顾性分析。10例儿科患者因传导性听力损失接受植入(14耳;植入时平均年龄9岁[范围3.8 - 17.2岁])。诊断包括耳道闭锁(n = 7)以及慢性耳部疾病和胆脂瘤(n = 3)。
植入MIAAD并处理皮肤并发症。
评估人口统计学特征、听力阈值、使用率及并发症情况。
佩戴磁性基板和声音处理器后,平均(标准差)助听听阈为20.2(6.0)dB听力级(HL),平均(标准差)功能增益为39.9(12.4)dB HL。无手术并发症。在佩戴声音处理器后评估不良结局。皮肤并发症发生率为35.7%,包括皮肤破损(n = 2)以及疼痛和红斑(n = 5),这导致这些患者减少了装置的使用。干预措施包括降低磁体强度、逐步增加佩戴时间、使用抗生素软膏、采取屏障保护措施以及使用Alloderm(LifeCell公司)进行耳道扩大再手术。无皮肤并发症的患者持续使用该装置,平均每日使用8至10小时。
MIAAD装置对传导性听力损失患儿的听力恢复水平与先前描述的其他干预方法相当。这份早期报告表明皮肤问题发生率较高,且需要改进植入方法、磁性基板适配及装置使用方法。我们建议在初次适配时降低磁体强度,采用逐步增加佩戴时间的方案,对有骨锚式助听器皮肤问题病史或接受过多次外科手术的患者谨慎处理,并就潜在的皮肤刺激问题对家长进行咨询。